Background
Parkinson disease (PD) is a long-term, progressive neurodegenerative disorder of the central nervous system, which results in motor and non-motor dysfunction. The disease is primarily related to loss of dopaminergic function.
Today, initial treatment for PD is typically with the anti-Parkinson medication levodopa (L-DOPA), and once levodopa becomes less effective dopamine agonists are being used. Currently there is no treatment to stop the progression nor cure PD, and thus there is an urgent need to develop new therapies for treating the disease. There is no cure for Parkinson’s disease, with current treatment mostly associated with Dopamine replacement therapy, directed at improving symptoms. The market of Parkinson’s disease treatments is driven by the growth in aging population and the associated increase in the prevalence of PD, however , there is currently no cure for Parkinson’s disease, with treatment mostly associated with Dopamine replacement therapy, directed at improving symptoms.
Our Innovation
The Researcher identified a possibly new target, with proposed mechanism of action associated with α-Syn toxicity in PD. Initial pre-clinical results suggest a novel therapeutic approach , using specific inhibitors to stop progression of Parkinson’s disease.
